On Thursday, 23 January 2014, Malebona Precious Matsoso (Director General of the South African National Department of Health) delivered the the following intervention at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7 on Access to essential medicines in response to the recent Pharmagate imbroglio.
On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for “western patients who can afford it.”
Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.” [UPDATE: The latest blog and transcript of Bayer CEO Marijn Dekkers’ full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.]
New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms
James K. Glassman. Merck said Glassman’s public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude. 2014: KEI testimony on WIPO broadcasting treaty, to House Judiciary Subcommittee on Courts, Intellectual Property, and Internet
Testimony of James Packard Love
Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the InternetMy 10 page written statement is here: /wp-content/uploads/JamesLove_Testimony.pdf
My 5 minute oral statement follows:
James Packard Love, Opening statement
Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the InternetWIPO hosts Conference on Open Innovation: Collaborative Projects and the Future of Knowledge (22-23 January 2014)
The World Intellectual Property Organization (WIPO) will host a “Conference on Open Innovation: Collaborative Projects and the Future of Knowledge” on 22-23 January 2014 at its headquarters in Geneva, Switzerland.
The origins of this conference on open collaborative development models is predicated upon Recommendation 36 of the WIPO Development Agenda which states:
Fast track trade bill fails to correct asymmetric secrecy of trade negotiations
Today Senators Bacus and Hatch introduced fast track legislation in the Senate. The words transparent or transparency appear 17 times in the 107 page bill, but only twice in connection with “Trade Institution Transparency.”
LESI to convene Global Technology Impact Forum (20-21 January 2014) at WIPO followed by dinner at the Mandarin Oriental
The Licensing Executives Society International, Inc. (LESI) is convening its annual Global Technology Impact Forum (GTIF) at the headquarters of the World Intellectual Property Organization (WIPO) from 20 to 21 January 2014 in Geneva, Switzerland. Although this international forum is hosted in Room A at WIPO headquarters, this event (at the time of publication of this blog) does not appear on the calendar of WIPO events for January 2014. Continue Reading
AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
